Abstract Number: 1352 • 2013 ACR/ARHP Annual Meeting
What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?
Background/Purpose: Clinical remission has now become the treatment goal in rheumatoid arthritis (RA), but it is not common in clinical practice. This study aimed to…Abstract Number: 1353 • 2013 ACR/ARHP Annual Meeting
Remission After Twelve Month Of Treatment In The Prague Early Rheumatoid Arhritis Cohort
Background/Purpose: Recent data have demonstrated that early treatment with disease modifying anti-rheumatic drugs (DMARDs) improves outcome in patients with Rheumatoid arthritis (RA). Early arthritis clinic…Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…Abstract Number: 1356 • 2013 ACR/ARHP Annual Meeting
Disease Activity Of Rheumatoid Arthritis Is Influenced By Seasonal Change, As Analyzed Based On a Nationwide Japanese Cohort Database
Background/Purpose: Previous studies have suggested that environmental factors, such as weather, humidity and seasonal change, may affect rheumatoid arthritis (RA). In the present study, we…Abstract Number: 1330 • 2013 ACR/ARHP Annual Meeting
Prednisone Use Associated With Worse Outcomes In Rheumatoid Arthritis Pregnancies
Background/Purpose: Prior reports suggest that disease activity in rheumatoid arthritis (RA) improves in the setting of pregnancy. However, prior studies report half of patients having…Abstract Number: 1316 • 2013 ACR/ARHP Annual Meeting
MMP3 As a Predictor Identifying a Subgroup Of Rheumatoid Patients Who Are Successfully Treated With Methotrexate (MTX) Alone But Still Subject To Radiographic Progression
Background/Purpose: To discover the prognostic factor identifying a subgroup with clinical relevant radiographic progression (CRRP) and rapid radiographic progressoion (RRP) among rheumatoid patients successfully treated…Abstract Number: 1317 • 2013 ACR/ARHP Annual Meeting
Methotrexate Optimization (ie introduction during the first 3 months and with dose escalation at 6 months at least at 20mg/w or 0.3mg/kg/w) Is Associated With Better Clinical Outcomes In Daily Practice: Results From The Espoir Cohort
Background/Purpose: Methotrexate (MTX) is recommended as the first DMARD in rheumatoid arthritis (RA) at a weekly dose of 20-25mg in combination with folic acid supplementation.…Abstract Number: 1318 • 2013 ACR/ARHP Annual Meeting
Prevalence and Impact Of Soft Tissue Manifestations In Early Inflammatory Arthritis: Results From The Canadian Early Arthritis Cohort
Background/Purpose: It is increasingly recognized that soft tissue inflammation in patients with inflammatory arthritis is frequent and might be of clinical importance. However, when therapeutic adjustments are made,…Abstract Number: 1319 • 2013 ACR/ARHP Annual Meeting
Diagnostic Value Of Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis
Background/Purpose: Citrulline and vimentin are some of the proteins used as antigens for anti-citrullinated proteins antibodies (ACPAs) detection for the diagnosis of rheumatoid arthritis (RA).…Abstract Number: 1320 • 2013 ACR/ARHP Annual Meeting
Categorization Of Rheumatoid Arthritis Subjects By Rheumatoid Factor and Anti-Cyclic Citrullinated Autoantibody Status Identifies Rheumatoid Arthritis Subjects With Different Characteristics
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated cyclic peptide (CCP) antibodies have been used to diagnose rheumatoid arthritis (RA) patients, although there is substantial heterogeneity among…Abstract Number: 1321 • 2013 ACR/ARHP Annual Meeting
Vasoactive Intestinal Peptide Serum Levels As a Marker Of Prognosis In Rheumatoid Arthritis
Background/Purpose: The current shift to earlier treatment of Rheumatoid Arthritis (RA) has a major unmet need in the availability of biomarkers to identify patients requiring more…Abstract Number: 1322 • 2013 ACR/ARHP Annual Meeting
Osteoprotegerin and TNF-Related Apoptosis Inducing Ligand Are Respectively Predictive Factors Of Remission and Erosion In Early Rheumatoid Arthritis Patients Included In The French Cohort Espoir
Background/Purpose: TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear factor…Abstract Number: 1323 • 2013 ACR/ARHP Annual Meeting
Plasma Leucine-Rich Alpha-2 Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis
Background/Purpose: Leucine-rich a2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats (LRRs). Though physiological functions of LRG have not been clarified yet, it has…Abstract Number: 1324 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Usefulness Of Interferon-Gamma Release Assays and Tuberculin Skin Test For Detection Of Latent Mycobacterium Tuberculosis Infection In Korean Rheumatic Patients With Biologic Agents
Background/Purpose: The screening for and treatment of latent tuberculosis infection (LTBI) before starting biologic agents is crucial to prevent reactivation and resultant serious infection. Several…Abstract Number: 1325 • 2013 ACR/ARHP Annual Meeting
A Novel Index To Identify Interstitial Lung Disease In Rheumatoid Arthritis Patients
A Novel Index to Identify Interstitial Lung Disease in Rheumatoid Arthritis Patients José Félix Restrepo1, Inmaculada del Rincón1, Roy W Haas1, Daniel F Battafarano2, Agustín Escalante1…